AV
ArriVent BioPharma, Inc.
AVBP · NASDAQ
$30.10 +0.53% (+$0.16)
1M -3.34%
Market Cap $1.40B
P/E Ratio -
Div. Yield -
ROE 50.26%
Piotroski F-Score Weak
2/9Valuation
53 /100
Fair P/B 3.82x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 20.76%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 47.92%
ROE 50.26%
ROA 41.48%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 14.16x
Int. coverage N/A
Stability
38 /100
Moderate Beta 1.36x
EPS volatility 40.17%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na AVBP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Zhengbin Yao
Employees
77
Headquarters
Newtown Square
Nadcházející události
16 LIS
Earnings
Upcoming earnings report